Synopsis: Advanced liver fibrosis (ALF) involves excessive accumulation of extracellular matrix proteins. It can occur in chronic liver diseases. In most patients, the condition eventually progresses into liver cirrhosis, failure, or malignancies and often needs resection. Treating ALF conditions for fibrosis regression can help to prevent further complications and reduce the need for liver transplantations.
This Journal Watch presents a summary of the clinical study titled, “ Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study ,” from the journal Hepatology International , August 2019. What was the need for the study? As data suggests, no established drug therapy specifically targets the liver fibrosis condition. Pirfenidone (PFD) is an anti-fibrotic drug known to inhibit transforming growth factor-beta 1…
